Conventional and experimental treatment of cerebral malaria

International Journal for Parasitology

Volumn 36, Issue 5, 2006, Pages 583-593

  Golenser, J ^a,b   McQuillan, J ^b   Hee, L ^b   Mitchell, A J ^b   Hunt, N H ^b  

^a HEBREW UNIVERSITY   (Israel)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cerebral malaria; Immunomodulation; Immunopathology; Plasmodium; Treatment

Indexed keywords

3,4 DIMETHOXY N [4 (3 NITROPHENYL)THIAZOL 2 YL]BENZENESULFONAMIDE; ANTIINFECTIVE AGENT; ARTEMETHER; ARTESUNATE; CHLOROQUINE; CURCUMIN; CURDLAN; CYCLOSPORIN; DIAZEPAM; DIHYDROARTEMISININ; GAMMA INTERFERON; GLUCOSE; INTERCELLULAR ADHESION MOLECULE 1; OSMOTIC DIURETIC AGENT; PENTOXIFYLLINE; PHENOBARBITAL; PHENYTOIN; QUINIDINE; QUININE; SULFONAMIDE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

DRUG PRESCRIBING; IMMUNE RESPONSE; INFECTIOUS DISEASE; MALARIA; NEUROLOGY; PARASITE; PATHOLOGY;

ACIDOSIS; BRAIN MALARIA; CLINICAL TRIAL; DISEASE COURSE; EXCHANGE BLOOD TRANSFUSION; HUMAN; HYPOGLYCEMIA; HYPOVOLEMIA; IMMUNE RESPONSE; IMMUNOMODULATION; INFECTION; INTRACRANIAL HYPERTENSION; NEUROTOXICITY; NONHUMAN; OSMOTIC DIURESIS; PARASITEMIA; PLASMODIUM FALCIPARUM; PRACTICE GUIDELINE; REVIEW; RODENT; SEIZURE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIMALARIALS; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOLOGIC FACTORS; MALARIA, CEREBRAL; MICE;

ARTESUNATE; CINCHONA PUBESCENS; PLASMODIUM FALCIPARUM; RODENTIA;

EID: 33646336877     PISSN: 00207519     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpara.2006.02.009     Document Type: Review

References (111)

1. Aceng J.R., Byarugaba J.S., and Tumwine J.K. Rectal artemether versus intravenous quinine for the treatment of cerebral malaria in children in Uganda: randomised clinical trial. Br. Med. J. 330 (2005) 317-318
2. Artavanis-Tsakonas K., and Riley E.M. Innate immune response to malaria: rapid induction of IFN-gamma from human NK cells by live Plasmodium falciparum-infected erythrocytes. J. Immunol. 169 (2002) 2956-2963
3. Bagot S., Nogueira F., Collette A., do Rosario V., Lemonier F., Cazenave P.A., and Pied S. Comparative study of brain CD8+T cells induced by sporozoites and those induced by blood-stage Plasmodium berghei ANKA involved in the development of cerebral malaria. Infect. Immun. 72 (2004) 2817-2826
4. Belnoue E., Kayibanda M., Vigario A.M., Deschemin J.C., van Rooijen N., Viguier M., Snounou G., and Renia L. On the pathogenic role of brain-sequestered alphabeta CD8+T cells in experimental cerebral malaria. J. Immunol. 169 (2002) 6369-6375
5. Belnoue E., Kayibanda M., Deschemin J.C., Viguier M., Mack M., Kuziel W.A., and Renia L. CCR5 deficiency decreases susceptibility to experimental cerebral malaria. Blood 101 (2003) 4253-4259
6. Binka F.N., Morris S.S., Ross D.A., Arthur P., and Aryeetey M.E. Patterns of malaria morbidity and mortality in children in northern Ghana.Trans. R. Soc. Trop. Med. Hyg. 4 (1994) 381-385
7. Blumer R.M., van Thien H., Ruiter A.F., Weverling G.J., vinh Thuan D., Endert E., Kager P.A., and Sauerwein H.P. Adiponectin and glucose production in patients infected with Plasmodium falciparum. Metabolism 54 (2005) 60-66
8. Boctor F.N. Red blood cell exchange transfusion as an adjunct treatment for severe pediatric falciparum malaria. Using automated or manual procedures. Pediatrics. 116 (2005) 592-595
9. Boutlis C.S., Weinberg J.B., Baker J., Bockarie M.J., Mgone C.S., Cheng Q., and Anstey N.M. Nitric oxide production and nitric oxide synthase activity in malaria-exposed Papua New Guinean children and adults show longitudinal stability and no association with parasitemia. Infect. Immun. 12 (2004) 6932-6938
10. Burk O., Arnold K.A., Nussler A.K., Schaeffeler E., Efimova E., Avery B.A., Avery M.A., Fromm M.F., and Eichelbaum M. Anti-malarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol. Pharmacol. 67 (2005) 1954-1965
11. Clark I.A. Cell-mediated immunity in protection and pathology of malaria. Parasitol. Today. 3 (1987) 300-305
12. Clark I.A., and Rockett K.A. Nitric oxide and parasitic disease. Adv. Parasitol. 37 (1996) 1-56
13. Clark I.A., Hunt N.H., and Cowden W.B. Oxygen-derived free radicals in the pathogenesis of parasitic disease. Adv. Parasitol. 25 (1986) 1-44
14. Clark C.J., Mackay G.M., Smythe G.A., Bustamante S., Stone T.W., and Phillips R.S. Prolonged survival of a murine model of cerebral malaria by kynurenine pathway inhibition. Infect. Immun. 8 (2005) 5249-5251
15. Combe B. Thalidomide: new indications?. Joint Bone Spine. 68 (2001) 582-587
16. Combes V., Rosenkranz A.R., Redard M., Pizzolato G., Lepidi H., Vestweber D., Mayadas T.N., and Grau G.E. Pathogenic role of P-selectin in experimental cerebral malaria: importance of the endothelial compartment. Am. J. Pathol. 164 (2004) 781-786
17. Combes V., Coltel N., Alibert M., van Eck M., Raymond C., Juhan-Vague I., Grau G.E., and Chimini G. ABCA1 gene deletion protects against cerebral malaria: potential pathogenic role of microparticles in neuropathology. Am. J. Pathol. 166 (2005) 295-302
18. Cooke A., Tonks P., Jones F.M., O'Shea H., Hutchings P., Fulford A.J., and Dunne D.W. Infection with Schistosoma mansoni prevents insulin dependent diabetes mellitus in non-obese diabetic mice. Parasite Immunol. 21 (1999) 169-176
19. Das B.K., Mishra S., Padhi P.K., Manish R., Tripathy R., Sahoo P.K., and Ravindran B. Pentoxifylline adjunct improves prognosis of human cerebral malaria in adults. Trop. Med. Int. Health. 8 (2003) 680-684
20. Davis T.M., Binh T.Q., Ilett K.F., Batty K.T., Phuong H.L., Chiswell G.M., Phuong V.D., and Agus C. Penetration of dihydroartemisinin into cerebrospinal fluid after administration of intravenous artesunate in severe falciparum malaria. Antimicrob. Agents. Chemother. 47 (2003) 368-370
21. Day N.P., Hien T.T., Schollaardt T., Loc P.P., Chuong L.V., Chau T.T., Mai N.T., Phu N.H., Sinh D.X., White N.J., and Ho M. The prognostic and pathophysiologic role of pro- and anti-inflammatory cytokines in severe malaria. J. Infect. Dis. 180 (1999) 1288-1297
22. de Souza J.B., and Riley E.M. Cerebral malaria: the contribution of studies in animal models to our understanding of immunopathogenesis. Microbes Infect. 4 (2002) 291-300
23. de Souza J.B., Williamson K.H., Otani T., and Playfair J.H. Early gamma interferon responses in lethal and nonlethal murine blood-stage malaria. Infect.Immun. 65 (1997) 1593-1598
24. Diallo T.O., Remoue F., Schacht A.M., Charrier N., Dompnier J.-P., Pillet S., Garraud O., N'Diaye A.A., Capron A., and Riveau G. Schistosomiasis co-infection in humans influences inflammatory markers in uncomplicated Plasmodium falciparum malaria. Parasite Immunol. 26 (2004) 365-369
25. Di Perri G., Di Perri I.G., Monteiro G.B., Bonora S., Hennig C., Cassatella M., Micciolo R., Vento S., Dusi S., and Bassetti D. Pentoxifylline as a supportive agent in the treatment of cerebral malaria in children. J. Infect. Dis. 171 (1995) 1317-1322
26. Dzeing-Ella A., Nze-Obiang P.C., Tchoua R., Planche T., Mboza B., Mbounja M., Muller-Roemer U., Jarvis J., Kendjo E., Ngou-Milama E., Kremsner P.G., Krishna S., and Kombila M. Severe falciparum malaria in Gabonese children: clinical and laboratory features. Malar J. 4 (2005) 1-8
27. Elhassan I.M., Hviid L., Jakobsen P.H., Giha H., Satti G.M., Arnot D.E., Jensen J.B., and Theander T.G. High proportion of subclinical Plasmodium falciparum infections in an area of seasonal and unstable malaria in Sudan. Am. J. Trop. Med. Hyg. 53 (1995) 78-83
28. Elliott D.E., Urban J.F.J.R., Argo C.K., and Weinstock J.V. Does the failure to acquire helminthic parasites predispose to Crohn's disease?. Fed. Am. Soc. Exp Biol. J. 14 (2000) 1848-1855
29. Engwerda C.R., Mynott T.L., Sawhney S., De Souza J.B., Bickle Q.D., and Kaye P.M. Locally up-regulated lymphotoxin alpha, not systemic tumor necrosis factor alpha, is the principle mediator of murine cerebral malaria. J. Exp. Med. 195 (2002) 1371-1377
30. Enwere G. A review of the quality of randomised clinical trials of adjunctive therapy for the treatment of cerebral malaria. Trop. Med. Int. Health. 10 (2005) 1171-1175
31. Engwerda C.R., Belnoue E., Gruner A.C., and Renia L. Experimental models of cerebral malaria. Curr. Top. Microbiol. Immunol. 297 (2005) 103-143
32. Esmon C.T. Coagulation and inflammation. J. Endotoxin. Res. 9 (2003) 192-198
33. Evans S.G., Morrison D., Kaneko Y., and Havlik I. The effect of curdlan sulphate on development in vitro of Plasmodium falciparum. Trans. R. Soc. Trop. Med. Hyg. 92 (1998) 87-89
34. Favre N., Ryffel B., and Rudin W. Parasite killing in murine malaria does not require nitric oxide production. Parasitology. 118 (1999) 139-143
35. Franke-Fayard B., Janse C.J., Cunha-Rodrigues M., Ramesar J., Buscher P., Que I., Lowik C., Voshol P.J., den Boer M.A., van Duinen S.G., Febbraio M., Mota M.M., and Waters A.P. Murine malaria parasite sequestration: CD36 is the major receptor, but cerebral pathology is unlinked to sequestration. Proc. Natl Acad. Sci. USA. 102 (2005) 11468-11473
36. Gbadoe A.D., Amenyah K.A., Agbere A.D., and Assimadi J.K. Decrease in death rate of cerebral malaria after systematic dextrose 10% infusion. Arch. Pediatr. 11 (2004) 866-867
37. Ginsburg H., and Golenser J. Glutathione is involved in the anti-malarial action of chloroquine and its modulation affects drug sensitivity of human and murine species Plasmodium. Redox Report. 8 (2003) 276-279
38. Golenser J., Domb A., Teomim D., Tsafack A., Nisim O., Ponka P., and Cabantchik Z.I. The treatment of animal models of malaria with iron chelators using a novel polymeric device for slow drug release. J. Pharmacol. Exp. Therap. 281 (1997) 1127-1135
39. Golenser J., Domb A., Kremsner P., and Luty A. Iron chelators as drugs against malaria pose a potential risk. Redox Report. 8 (2003) 268-271
40. Good M.F., Xu H., Wykes M., and Engwerda C.R. Development and regulation of cell-mediated immune responses to the blood stages of malaria: implications for vaccine research. Annu. Rev. Immunol. 23 (2005) 69-99
41. Grau G.E., Fagardo L.F., Piguet P.F., Allet B., Lambert P.H., and Vassalli P. Tumor necrosis factor (cachectin) as an essential mediator in murine cerebral malaria. Science 237 4819 (1987) 1210-1212
42. Grau G.E., Gretener D., and Lambert P.H. Prevention of murine cerebral malaria by low-dose cyclosporin A. Immunology 61 (1987) 521-525
43. Grau G.E., Piguet P.F., Vassalli P., and Lambert P.H. Tumor-necrosis factor and other cytokines in cerebral malaria: experimental and clinical data. Immunol. Rev. 112 (1989) 49-70
44. Hansen A.M., Ball H.J., Mitchell A., Miu J.M., Takikawa O., and Hunt N.H. Increased expression of indoleamine 2,3-dioxygenase in murine malaria infection is predominantly localised to the vascular endothelium. Int. J. Parasitol. 39 (2004) 1309-1319
45. Hansen D.S., Evans K.J., D'Ombrain M.C., Bernard N.J., Sexton A.C., Buckingham L., Scalzo A.A., and Schofield L. The natural killer complex regulates severe malarial pathogenesis and influences acquired immune responses to Plasmodium berghei ANKA. Infect. Immun. 73 (2005) 2288-2297
46. Helmby H., Kullberg M., and Trove-Blomberg M. Altered immune responses in mice with concomitant Schistosoma mansoni and Plasmodium chabaudi infections. Infect. Immun. 66 (1998) 5167-5174
47. Hensmann M., and Kwiatkowsky D. Cellular basis of early cytokine response to Plasmodium falciparum. Infect. Immun. 69 (2001) 2364-2371
48. Hashimoto Y. Structural development of biological response modifiers based on thalidomide. Bioorg. Med. Chem. 10 (2002) 461-479
49. Havlik I., Looareesuwan S., Vannaphan S., Wilairatana P., Krudsood S., Thuma P.E., Kozbor D., Watanabe N., and Kaneko Y. Curdlan sulphate in human severe/cerebral Plasmodium falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 99 (2005) 333-340
50. Hemmer C.J., Hort G., Chiwakata C.B., Seitz R., Egbring R., Gaus W., Hogel J., Hassemer M., Nawroth P.P., Kern P., and Dietrich M. Supportive pentoxifylline in falciparum malaria: no effect on tumor necrosis factor alpha levels or clinical outcome: a prospective, randomised, placebo-controlled study. Am. J. Trop. Med. Hyg. 56 (1997) 397-403
51. Ho M., Sexton M.M., Tongtawe P., Looareesuwan S., Suntharasamai P., and Webster H.K. Interleukin-10 inhibits tumor necrosis factor production but not antigen-specific lymphoproliferation in acute Plasmodium falciparum malaria. J. Infect. Dis. 172 (1995) 838-844
52. Ho M., Schollaardt T., Snape S., Looareesuwan S., Suntharasamai P., and White N.J. Endogenous interleukin-10 modulates proinflammatory response in Plasmodium falciparum malaria. J. Infect. Dis. 178 (1998) 520-525
53. Hunt N.H., and Grau G.E. Cytokines: accelerators and brakes in the pathogenesis of cerebral malaria.Trends. Immunol. 24 (2003) 491-499
54. Hunt, N.H. Golenser, J., Chan-Ling, T. Parekh, S., Rae, C., Potter, S., Medana, I.M. Miu, J., Ball, H.J., 2006. Immunopathogenesis of cerebral malaria. Int. J. Parasitol. 36, (in press).
55. Kokwaro G.O., Ogutu B.R., Muchohi S.N., Otieno G.O., and Newton C.R. Pharmacokinetics and clinical effect of phenobarbital in children with severe falciparum malaria and convulsions. Br. J. Clin. Pharmacol. 56 (2003) 453-457
56. Kremsner P.G., Grundmann H., and Neifer S. Pentoxifylline prevents murine cerebral malaria. J. Infect. Dis. 164 (1991) 605-608
57. Kremsner P.G., Winkler S., Brandts C., Wildling E., Jenne L., Graninger W., Prada J., Bienzle U., Juillard P., and Grau G.E. Prediction of accelerated cure in Plasmodium falciparum malaria by the elevated capacity of tumor necrosis factor production. Am. J. Trop. Med. Hyg. 53 (1995) 532-538
58. Kwiatkowski D., and Bate C. Inhibition of tumour necrosis factor (TNF) production by antimalarial drugs used in cerebral malaria. Trans. R. Soc. Trop. Med. Hyg. 89 (1995) 215-216
59. Le Hesran J.Y., Akiana J., Ndiaye el H.M., Dia M., Senghor P., and Konate L. Severe malaria attack is associated with high prevalence of Ascaris lumbricoides infection among children in rural Senegal. Trans. R. Soc. Trop. Med. Hyg. 98 (2004) 397-399
60. Looareesuwan S., Wilairatana P., Vannaphan S., Wanaratana V., Wenisch C., Aikawa M., Brittenham G., Graninger W., and Wernsdorfer W.H. Pentoxifylline as an ancillary treatment for severe falciparum malaria in Thailand. Am. J. Trop. Med. Hyg. 58 (1998) 348-353
61. Lyke K.E., Dicko A., Dabo A., Sanagare L., Kone A., Coulibaly D., Guindo A., Traore K., Daou M., Diarra I., Sztein M.B., Plowe C.V., and Doumbo O.K. Association of Schistosoma haematobium infection with protection against acute Plasmodium falciparum malaria in Malain children. Am. Trop. Med. Hyg. 73 (2005) 1124-1130
62. Maitland K., and Newton C.R. Acidosis of severe falciparum malaria: heading for a shock?. Trends. Parasitol. 21 (2005) 11-16
63. Maitland K., Pamba A., English M., Peshu N., Marsh K., Newton C., and Levin M. Randomized trail of volume expansion with albumin or saline in children with severe malaria: preliminary evidence of albumin benefit. Clin. Infect. Dis. 40 (2005) 538-545
64. Malaguarnera L., Imbesi R.M., Pignatelli S., Simpore J., Malaguarnera M., and Musumeci S. Increased levels of interleukin-12 in Plasmodium falciparum malaria: correlation with the severity of disease. Parasite. Immunol. 24 (2002) 387-389
65. Maneerat Y., Viriyavejakul P., Punpoowong B., Jones M., Wilairatana P., Pongponratn E., Turner G.D., and Udomsangpetch R. Inducible nitric oxide synthase expression is increased in the brain in fatal cerebral malaria. Histopathology. 37 (2000) 269-277
66. Manish R., Tripathy R., and Das B.K. Plasma glucose and tumour necrosis factor-alpha in adult patients with severe falciparum malaria. Trop. Med. Int. Health. 8 (2003) 125-128
67. May J., Lell B., Luty A.J., Meyer C.G., and Kremsner P.G. Plasma interleukin-10: tumor necrosis factor (TNF)-alpha ratio is associated with TNF promoter variants and predicts malarial complications. J. Infect. Dis. 182 (2000) 1570-1573
68. Mayanja-Kizza H. Clinical expression of malaria: why Mary and not John. Malaria Infection in Africa 2 (1995) 26-30
69. Mazier D., Nitcheu J., and Idrissa-Boubou M. Cerebral malaria and immunogenetics. Parasite. Immunol. 22 (2000) 613-623
70. Medana I.M., Hien T.T., Day N.P., Phu N.H., Mai N.T.H., Chu'ong L.V., Chau T.T.H., Taylor A., Salahifar H., Stocker R., Smythe G., Turner G.D.H., Farrar J., White N.J., and Hunt N.H. The clinical significance of cerebrospinal fluid levels of kynurenine pathway metabolites and lactate in severe malaria. J. Infect. Dis. 185 (2002) 650-656
71. Mitchell A.J., Hansen A.M., Hee L., Ball H.J., Potter S.M., Walker J.C., and Hunt N.H. Early cytokine production is associated with protection from murine cerebral malaria. Infect. Immun. 73 (2005) 5645-5653
72. Modiano D., Petrarca V., Sirima B.S., Nebie I., Diallo D., Esposito F., and Coluzzi M. Different response to Plasmodium falciparum malaria in west African sympatric ethnic groups. Proc. Natl. Acad. Sci. 93 (1996) 13206-13211
73. Mordmuller B.G., Metzger W.G., Juillard P., Brinkman B.M., Verweij C.L., Grau G.E., and Kremsner P.G. Tumor necrosis factor in Plasmodium falciparum malaria: high plasma level is associated with fever, but high production capacity is associated with rapid fever clearance. Eur. Cytokine. Netw. 8 (1997) 29-35
74. Mshana R.N., Boulandi J., Mshana N.M., Mayombo J., and Mendome G. Cytokines in the pathogenesis of malaria: levels of IL-I beta, IL-4, IL-6, TNF-alpha and IFN-gamma in plasma of healthy individuals and malaria patients in a holoendemic area. J. Clin. Lab. Immunol. 34 (1991) 131-139
75. Muir, M., 2003. DMSO: many uses, much controversy. www. dmso.org/articles/information/muir.htm
76. Muniz-Junqueira M.I., Silva F.O., de Paula-Junior M.R., and Tosta C.E. Thalidomide influences the function of macrophages and increases the survival of Plasmodium berghei-infected CBA mice. Acta. Trop. 94 (2005) 128-138
77. Nacher M., Singhasivanon P., Yimsamran S., Manibunyong W., Thanyavanich N., Wuthisen R., and Looareesuwan S. Intestinal helminth infections are associated with increased incidence of Plasmodium falciparum malaria in Thailand. J. Parasitol. 88 (2002) 55-58
78. Nacher M., Singhasivanon P., Traore B., Vannaphan S., Gay F., Chindanond D., Franetich J.F., Mazier D., and Looareesuwan S. Helminth infections are associated with protection from cerebral malaria and increased nitrogen derivatives concentrations in Thailand. Am.J. Trop. Med. Hyg. 66 (2002) 304-309
79. Nitcheu J., Bonduelle O., Combadiere C., Tefit M., Seilhean D., Mazier D., and Combadiere B. Perforin-dependent brain-infiltrating cytotoxic CD8+T lymphocytes mediate experimental cerebral malaria pathogenesis. J. Immunol. 70 (2003) 2221-2228
80. Newton C.R., and Krishna S. Severe falciparum malaria in children: current understanding of pathophysiology and supportive treatment. Pharmacol. Ther. 79 (1998) 1-53
81. Newton C.R., Crawley J., Sowumni A., Waruiru C., Mwangi I., English M., Murphy S., Winstanley P.A., Marsh K., and Kirkham F.J. Intracranial hypertension in Africans with cerebral malaria. Arch Dis Child. 76 (1997) 219-226
82. Newton C.R., Hien T.T., and White N. Neurological aspects of tropical disease: Cerebral malaria. J. Neurol. Neurosurg. Psychiatry. 69 (2000) 433-441
83. Njuguna P., and Newton C. Management of severe falciparum malaria. J. Postgrad. Med. 50 (2004) 45-50
84. Nyangoto E.O. Cell-mediated effector molecules and complicated malaria. Int. Arch. Allergy. Immunol. 137 (2005) 326-342
85. Okoromah C.A., and Afolabi B.B. Mannitol and other osmotic diuretics as adjuncts for treating cerebral malaria. Cochrane Database Syst Rev. 18 (2005) CD004615
86. Paterson J.C., Garside P., Kennedy M.W., and Lawrence C.E. Modulation of a heterologous immune response by the products of Ascaris suum. Infect. Immun. 70 (2002) 6058-6067
87. Pino P., Vouldoukis I., Kolb J.P., Mahmoudi N., Desportes-Livage I., Bricaire F., Danis M., Dugas B., and Mazier D. Plasmodium falciparum-infected erythrocyte adhesion induces caspase activation and apoptosis in human endothelial cells. J. Infect. Dis. 187 (2003) 1283-1290
88. Prasad K., and Garner P. Steroids for treating cerebral malaria. Cochrane Database Syst. Rev. 2 (2000) CD000972
89. Reddy R.C., Vatsala P.G., Keshamouni V.G., Padmanaban G., and Rangarajan P.N. Curcumin for malaria therapy. Biochem. Biophys. Res. Commun. 326 (2005) 472-474
90. Sanni L.A., Thomas S.R., Tattam B.N., Moore D.E., Chaudhri G., Stocker R., and Hunt N.H. Dramatic changes in oxidative tryptophan metabolism along the kynurenine pathway in experimental cerebral and noncerebral malaria. Am. J. Pathol. 152 (1998) 611-619
91. Sanni L.A., Fu S., Dean R.T., Blomfield G., Stocker R., Chandhri G., Dinauer M.C., and Hunt N.H. Are reactive oxygen species involved in the pathogenesis of murine cerebral malaria?. J. Infect. Dis. 179 (1999) 217-222
92. Sanni L.A., Jarra W., Li C., and Langhorne J. Cerebral edema and cerebral hemorrhages in interleukin-10-deficient mice infected with Plasmodium chabaudi. Infect. Immun. 72 (2004) 3054-3058
93. Sarfo B.Y., Singh S., Lillard J.W., Quarshie A., Gyasi R.K., Armah H., Adjei A.A., and Jolly P. The cerebral-malaria-associated expression of RANTES, CCR3 and CCR5 in post-mortem tissue samples. Ann. Trop. Med. Parasitol. 98 (2004) 297-303
94. Sokhna C., Le Hesran Y.J., Mbaye P.A., Akiana J., Camara P., Diop M., Ly A., and Druilhe P. Increase of malaria attacks among children presenting concomitant infection by Schistosoma mansoni in Senegal. Malar. J. 15 (2004) 43
95. Stevenson M.M., Tam M.F., Wolf S.F., and Sher A. IL-12-induced protection against blood-stage Plasmodium chabaudi AS requires IFN-gamma and TNF-alpha and occurs via a nitric oxide-dependent mechanism. J. Immunol. 155 (1995) 2545-2556
96. Summers R.W., Elliott D.E., and Weinstock J.V. Why Trichuris suis should prove safe for use in inflammatory bowel diseases. Inflamm. Bowel Dis. 8 (2005) 783-784
97. Sun G., Chang W.L., Li J., Berney S.M., Kimpel D., and van der Heyde H.C. Inhibition of platelet adherence to brain microvasculature protects against severe Plasmodium berghei malaria.Infect. Immun 71 (2003) 6553-6561
98. Teixeira L.K., Fonseca B.P., Vieira-de-abreu A., Barboza B.A., Robbs B.K., Bozza P.T., and Viola J.P. IFN-{gamma} Production by CD8+T Cells Depends on NFAT1 Transcription Factor and Regulates Th Differentiation. J. Immunol. 175 (2005) 5931-5939
99. Torre D., Speranza F., Giola M., Matteelli A., Tambini R., and Biondi G. Role of Th1 and Th2 cytokines in immune response to uncomplicated Plasmodium falciparum malaria. Clin. Diagn. Lab. Immunol. 9 (2002) 348-351
100. Turner G. Cerebral malaria. Brain Pathol. 7 (1997) 569-582
101. van der Kleij D., Latz E., Brouwers J.F., Kruize Y.C., Schmitz M., Kurt-Jones E.A., Espevik T., de Jong E.C., Kapsenberg M.L., Golenbock D.T., Tielens A.G., and Yazdanbakhsh M. A novel host-parasite lipid cross-talk, Schistosomal lyso-phosphatidylserine activates toll-like receptor 2 and affects immune polarisation. J. Biol. Chem. 50 (2002) 48122-48129
102. van Hensbroek M.B., Palmer A., Onyiorah E., Schneider G., Jaffar S., Dolan G., Memming H., Frenkel J., Enwere G., Bennett S., Kwiatkowski D., and Greenwood B. The effect of a monoclonal antibody to tumor necrosis factor on survival from childhood cerebral malaria. J. Infect. Dis. 174 (1996) 1091-1097
103. van Thien H., Ackermans M.T., Dekker E., Thanh-Chien V.O., Le T., Endert E., Kager P.A., Romijn J.A., and Sauerwein H.P. Glucose production and gluconeogenesis in adults with cerebral malaria. QJM. 94 (2001) 709-715
104. Voza T., Vigario A.M., Belnoue E., Gruner A.C., Deschemin J.C., Kayibanda M., Delmas F., Janse C.J., Franke-Fayard B., Waters A.P., Landau I., Snounou G., and Renia L. Species-specific inhibition of cerebral malaria in mice coinfected with Plasmodium spp. Infect. Immun. 73 (2005) 4777-4786
105. Waller D., Crawley J., Nosten F., Chapman D., Krishna S., Craddock C., Brewster D., and White N.J. Intracranial pressure in childhood cerebral malaria. Trans. R. Soc. Trop. Med. Hyg. 85 (1991) 362-364
106. Wassmer S.C., Lepolard C., Traore B., Pouvelle B., Gysin J., and Grau G.E. Platelets reorient Plasmodium falciparum-infected erythrocyte cytoadhesion to activated endothelial cells. J. Infect. Dis. 189 (2004) 180-189
107. Watt G., Jongsakul K., and Ruangvirayuth R. A pilot study of N-acetylcysteine as adjunctive therapy for severe malaria. QJM 95 (2002) 285-290
108. Wenisch C., Parschalk B., Narzt E., Looareesuwan S., and Graninger W. Elevated serum levels of IL-10 and IFN-gamma in patients with acute Plasmodium falciparum malaria. Clin. Immunol. Immunopathol. 74 (1995) 115-117
109. Yadav V.S., Mishra K.P., Singh D.P., Mehrotra S., and Singh V.K. Immunomodulatory effects of curcumin. Immunopharmacol. Immunotoxicol. 27 (2005) 485-497
110. Yanez D.M., Manning D.D., Cooley A.J., Weidanz W.P., and Van der Heyde H.C. Participation of lymphocyte subpopulations in the pathogenesis of experimental murine cerebral malaria. J. Immunol. 157 (1996) 1620-1624
111. Yoshida A., Maruyama H., Kumagai T., Amano T., Kobayashi F., Zhang M., Himeno K., and Ohta N. Schistosoma mansoni infection cancels the susceptibility to Plasmodium chabaudi through induction of type 1 immune responses in A/J mice. Int. Immunol. 12 (2000) 1117-1125